Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:
An2 Therapeutics Inc (ANTX)
An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
The Five Biotech Stocks Every Investor Should Know About BayStreet.ca - Tue Sep 5, 9:43AM CDT

Avalon GloboCare Corp., (NASDAQ: ALBT) a developer of innovative precision diagnostics and provider of clinical laboratory services just announced that the United States Patent and Trademark Office (USPTO)...

ALBT : 0.5139 (+2.78%)
INSM : 25.02 (-0.32%)
VIR : 9.49 (-3.36%)
CODX : 1.1800 (unch)
ANTX : 17.57 (+7.59%)
A Potentially Revolutionary Tuberculosis Test Can Produce Results in 24 Hours BayStreet.ca - Wed Aug 30, 8:23AM CDT

With a rising prevalence of chronic diseases, we’re starting to see higher demand for clinical lab services. That being said, it’s no surprise that, according to Market.Us, the global market for clinical...

INSM : 25.02 (-0.32%)
VIR : 9.49 (-3.36%)
CODX : 1.1800 (unch)
ANTX : 17.57 (+7.59%)
ALBT : 0.5139 (+2.78%)
Brii Biosciences Provides Latest Clinical Development and Corporate Updates PR Newswire - Wed Jul 5, 6:18PM CDT

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from...

VIR : 9.49 (-3.36%)
VBIV : 0.6152 (+0.84%)
ANTX : 17.57 (+7.59%)
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference Business Wire - Mon May 1, 6:00AM CDT

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 17.57 (+7.59%)
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights Business Wire - Wed Mar 29, 3:01PM CDT

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported...

ANTX : 17.57 (+7.59%)
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results PR Newswire - Fri Mar 24, 12:18AM CDT

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 9.49 (-3.36%)
VBIV : 0.6152 (+0.84%)
ANTX : 17.57 (+7.59%)
AN2 Therapeutics to Participate in Upcoming Investor Conferences Business Wire - Tue Feb 28, 3:10PM CST

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 17.57 (+7.59%)
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference Business Wire - Tue Jan 31, 3:10PM CST

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 17.57 (+7.59%)
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease Globe Newswire - Wed Jun 29, 2022

AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an...

ANTX : 17.57 (+7.59%)
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates Globe Newswire - Tue May 10, 2022

On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing...

ANTX : 17.57 (+7.59%)

Barchart Exclusives

Live Cattle Supply Challenges Still Persist and Support a Seasonal Buy Opportunity Barchart - Thu Nov 30, 3:39PM CST
The cattle market continues to experience a period of constrained supplies, a trend expected to persist in the coming year. The fundamentals of the challenges caused by a drought and elevated input prices have not changed. The recent sell-off in Live Cattle may have created a seasonal buy pattern worth investigating. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot